Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SPON2 antisense RNA 1 (SPON2-AS1)
- Target
- SPON2-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Other (non-coding RNA)
01
Overview
SPON2 antisense RNA 1 (SPON2-AS1), also known as AC092535.4, is a long non-coding RNA located antisense to the SPON2 gene. SPON2-AS1 has been identified as a novel prognostic biomarker in several cancers, including uveal melanoma and clear cell renal cell carcinoma, where its high expression is associated with poor prognosis. Functional studies show that reducing SPON2-AS1 expression inhibits cancer cell proliferation and migration, suggesting a possible oncogenic role. Like other lncRNAs, SPON2-AS1 may regulate neighboring gene (SPON2) expression or act more broadly via mechanisms such as chromatin remodeling and transcriptional interference, but its precise molecular functions remain to be elucidated. While it is considered a promising biomarker and potential therapeutic target in cancer, no approved drugs currently modulate its activity.
- Other names
- AC092535.4SPON2-AS1Spondin 2 antisense RNA 1
02
Mechanism of action
Not applicable. No specific drugs targeting SPON2-AS1 have reported mechanisms; lncRNA-based therapeutics could involve antisense oligonucleotides or RNA interference if developed
03
Biological functions
Regulation of gene expression (putative/transcriptional regulation in cis or trans, as with other lncRNAs)Cellular proliferation and migration in cancer (based on knockdown studies in uveal melanoma cells)
04
Disease associations
Cancer (notably uveal melanoma, clear cell renal cell carcinoma)Potential involvement in other cancers, given regulatory lncRNA mechanisms
05
Safety considerations
None reported yet, as there are no direct therapies targeting SPON2-AS1 in clinical use.lncRNA-targeting approaches, in general, may face typical RNA therapeutics challenges such as off-target effects or immune activation.
06
Biomarkers
SPON2-AS1 (AC092535.4) expression itself is reported as a prognostic biomarker, notably for uveal melanoma and clear cell renal cell carcinomaHigher expression correlates with lower survival rates in clear cell renal cell carcinoma
Beyond the preview
Go deeper on SPON2 antisense RNA 1 (SPON2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPON2 antisense RNA 1 (SPON2-AS1).